285 Patient-reported Outcomes from the Phase 3, Randomized, Double-Blind, Placebo-Controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 Study of Pembrolizumab Plus Concurrent Chemoradiotherapy in Patients with High-Risk Locally Advanced Cervical Cancer